Cilcare Updates License Agreement with Sanofi, Brings Pharma Giant on as Equity Holder
The biotech secures improved royalty terms on its two lead hearing loss programs, CIL001 and CIL003, while Sanofi takes a minority stake in the company.
Tag: CILcare
All
Latest
All
Latest
CILcare Welcomes Experts in Auditory Science
Biotech company CILcare adds four hearing experts to its Scientific Advisory Board: Keith Darrow, Stéphane Maison, Aimo Kannt, and Dona Jayakody. The SAB will help develop CILcare's synaptopathy pipeline, which targets early markers of neurocognitive and inflammatory diseases.
All
Latest
Article Explores COVID-19 Treatment and Auditory Safety
Repurposing approved compounds carries both opportunities and risks, including a high risk of ototoxicity based on existing data on the drug classes under consideration.
